Heterocyclic immunomodulator
AssigneeBeijing Innocare Pharma Tech Co., Ltd.
InventorsXiangyang Chen, Yucheng Pang
Life of this patent
Estimating the term…
Abstract
The present invention relates to heterocyclic compounds as immunomodulators, or pharmaceutically acceptable salts thereof. Specifically, the present invention relates to compounds as represented by general formula (I) and pharmaceutically acceptable salts thereof. The present invention also relates to methods for preparing the compounds or the pharmaceutically acceptable salts thereof. The compounds can be used for treating and/or preventing tumors, inflammations or immune diseases.
Claims13
A compound represented by general formula (I), or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof:
- wherein:
- ring A is a nitrogen-containing 4- to 10-membered heterocycle;
- R1 is D or halogen;
- R2 and R3 are each independently selected from H, D, halogen, cyano, C1-6alkyl, C3-6cycloalkyl or 3- to 8-membered heterocyclyl, but both cannot be H and/or D at the same time, or R2 and R3 together with the carbon atoms attached thereto form C3-6cycloalkane or 3- to 8-membered heterocycle;
- R4 is D, halogen, cyano, oxo, C1-6alkyl, C3-6cycloalkyl, —OC1-6alkyl, —C(O)C1-6alkyl, —C(O)C3-6cycloalkyl, —S(O)2C1-6alkyl, —S(O)2C3-6cycloalkyl, aryl or heteroaryl, wherein one or more hydrogens of the alkyl, the cycloalkyl, the aryl and the heteroaryl are optionally substituted with D, halogen, cyano, C1-2alkyl or fluoroC1-2alkyl;
- m is an integer of 0-4;
- and
- n is an integer of 0-2.
The compound according to any of the previous claims or a pharmaceutically acceptable salt, a stable isotope derivative, or an isomer thereof, wherein m is 0.
Dependencies are inferred from the claim text.